Dry eye can feel like sandpaper every time you blink. For people with Sjögren’s syndrome, that gritty, burning feeling is a daily battle. Now, a new analysis suggests stem cell therapy may offer meaningful relief.
Sjögren’s syndrome is an autoimmune condition that attacks moisture producing glands. It often causes severe dry eye and dry mouth. Millions of adults live with this condition, and many say current drops and medications do not give enough comfort. That gap is why researchers are looking at stem cells.
But here is the twist. Stem cell therapy is not a new idea. What is different is how it is being tested for dry eye. Instead of just adding moisture, stem cells may help calm the immune attack and support the eye’s natural tear film. Think of the tear film as a thin, protective shield over the eye. In Sjögren’s syndrome, that shield breaks down. Stem cells may act like a repair crew, patching weak spots and calming inflammation.
To understand the biology, picture a traffic jam on a busy highway. Inflammation blocks the normal flow of healing signals. Stem cells can act like a traffic controller, clearing the jam so the body’s own repair system can move through. They also release gentle signals that tell nearby cells to calm down and rebuild.
A recent systematic review and meta-analysis pulled together the best available evidence on this topic. The study was published in Frontiers in Medicine in April 2026. The authors searched major medical databases through January 2026 and found five studies involving 114 patients with dry eye caused by Sjögren’s syndrome. They analyzed how stem cell therapy changed symptoms and tear function, and they tracked safety.
The results show clear improvements in key measures of dry eye. The most patient relevant finding is the change in the Ocular Surface Disease Index, or OSDI. This is a standard survey that measures eye discomfort, vision, and environmental triggers. After stem cell therapy, OSDI scores dropped by about 15 points on average. That is a meaningful shift for someone who lives with daily eye pain.
Tear production also improved. The Schirmer test measures how much tear fluid the eye makes over five minutes. After treatment, scores rose by nearly four millimeters on average. That may sound small, but it can translate into less burning and better comfort. The time it takes for the tear film to break up also improved. The first non invasive keratography tear film break up time, or NIKBUT, increased by about three seconds. A longer NIKBUT means the tear film stays stable longer, which protects the eye surface.
This does not mean stem cell therapy is ready for every clinic.
The safety profile showed short term side effects. About 14 percent of patients reported injection pain at four weeks. Ocular discomfort was reported by 16 percent, and periorbital swelling by 14 percent. Blurred vision occurred in about 21 percent, and tingling around the eye in about 15 percent. These numbers come from small studies, so they should be interpreted with care. The analysis did not find a statistically significant change in the Oxford score, which grades damage to the eye surface. That suggests surface healing may take longer or need different measures.
An expert perspective helps place these findings in context. The authors note that stem cell therapy appears to improve symptoms and tear function, but short term side effects mean benefits and risks must be weighed carefully. Close follow up and rigorous monitoring are essential. This is consistent with how new therapies are introduced in eye care.
What this means for you is straightforward. If you have Sjögren’s syndrome and severe dry eye, stem cell therapy may become an option in the future. Right now, it is still experimental and not widely available. Talk with your eye doctor about current treatments and whether you might be a candidate for clinical trials. Keep using proven dry eye strategies, such as artificial tears, warm compresses, and prescription anti inflammatory drops, while staying informed about new options.
The study has limitations. It included only five studies and 114 patients. The follow up times varied, and the types of stem cells used differed across studies. Small samples can make results less certain, and they can miss rare side effects. Larger, longer trials are needed to confirm these findings and to understand who benefits most.
Looking ahead, researchers will likely run more controlled trials with longer follow up. They will compare different stem cell types and delivery methods, and they will track both symptoms and eye surface health over time. Regulatory review will also be needed before this therapy becomes widely available. For now, the evidence points to real promise, but patience and careful monitoring are key.
